Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8371056 | 1.00 | MMP12 (0.49) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL3115450 | 0.88 | TRPA1 (0.58) | TRPA1SLC6A3 | |
| SCHEMBL4799370 | 0.86 | MMP2 (0.55) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL27688499 | 0.81 | TSHR (0.44) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL409924 | 0.81 | TAAR1 (0.45) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL2074824 | 0.80 | TDP1 (0.52) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL448011 | 0.80 | TRPA1 (0.56) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL2077325 | 0.80 | TDP1 (0.52) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL2074517 | 0.80 | TDP1 (0.52) | MMP12DPP4MMP2MMP9MMP13 | |
| SCHEMBL10247192 | 0.79 | CYP1A2 (0.43) | MMP12DPP4MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104745649-B | A kind of biological preparation method of fosamprenavir intermediate | 苏州汉酶生物技术有限公司 | 2018-03-09 | — | — | CN | claimed |
| CN-104911224-B | Method for catalytic synthesis of atazanavir intermediate | 南京工业大学 | 2018-12-25 | — | — | CN | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| CN-104745649-B | A kind of biological preparation method of fosamprenavir intermediate | 苏州汉酶生物技术有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-9884820-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160362373-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | disclosed |
| US-9446022-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-20 | — | — | US | disclosed |
| US-9095572-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140343018-A1 | Anti-depression Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-11-20 | — | — | US | disclosed |
| US-8877797-B2 | Methods for treating Parkinson's disease using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-04 | — | — | US | disclosed |
| US-8735440-B2 | Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| US-7851570-B2 | Precatalysts useful in polyolefin polymerization reactions | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080207853-A1 | Precatalysts useful in polyolefin polymerization reactions | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | MMP12 638/4885DPP4 2972/4885MMP2 1294/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | MMP12 701/4885DPP4 3059/4885MMP2 1437/4885 |
| US-20180127367-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MMP12 701/4885DPP4 3059/4885MMP2 1437/4885 |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MMP12 614/4885DPP4 3042/4885MMP2 1254/4885 |
| US-20140343018-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | MMP12 781/4885DPP4 2904/4885MMP2 1266/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MMP12 701/4885DPP4 3059/4885MMP2 1437/4885 |
| US-20160362373-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MMP12 701/4885DPP4 3059/4885MMP2 1437/4885 |
| US-20080207853-A1 | Precatalysts useful in polyolefin polymerization reactions | PPOX, PORCN, PTGES | MMP12 4560/4885DPP4 4251/4885MMP2 4617/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | MMP12 781/4885DPP4 2904/4885MMP2 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.